Skip to main content
Clinical Trials/EUCTR2004-003807-19-GB
EUCTR2004-003807-19-GB
Active, not recruiting
Phase 1

A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration Study

Merck Sharp & Dohme Ltd0 sites600 target enrollmentFebruary 24, 2005

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Mixed hyperlipidemia
Sponsor
Merck Sharp & Dohme Ltd
Enrollment
600
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 24, 2005
End Date
September 29, 2005
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Merck Sharp & Dohme Ltd

Eligibility Criteria

Inclusion Criteria

  • a.Patient has an LDL\-C 130 through 220 mg/dL (3\.37 through 5\.70 mmol/L) for non\-diabetics; LDL\-C 100 through 180 mg/dL (2\.59 through 4\.66 mmol/L) for diabetics, at Visit 2\.
  • b.Patient has triglycerides 150 through 500 mg/dL (1\.71 through 5\.70 mmol/L). \[per central laboratory reference ranges] at Visit 2\.
  • c.Patient has creatine phosphokinase (CPK) \=2 x upper limit of normal (ULN) \[per central laboratory reference ranges] at Visit 2\.
  • d.Patient has alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \=1\.5 x upper limit of normal (ULN) \[per central laboratory reference ranges] at Visit 2\.
  • Are the trial subjects under 18?
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • a.You are less than 18 years of age or greater than 79 years of age.
  • b.You are pregnant, breastfeeding, or planning to become pregnant during this study.
  • c.You are a woman able to become pregnant and are not willing to use an acceptable method of birth control. You must be willing to use this birth control starting at Visit 1 and continuing 14 days past the last study dose. The study doctor or staff will discuss which methods of birth control are acceptable for this study.
  • d.You are a woman and have taken cyclical hormone birth control or hormone replacement within 8 weeks of Visit 3\.
  • e.You have chronic heart failure, uncontrolled irregular heart beats or a history of heart disease. The study doctor or staff will discuss this with you.
  • f.You have diabetes and are taking lipid lowering medication called statins.
  • g.You have a history of cholelithiasis (gallbladder problems) and you have not had your gallbladder removed.
  • h.You have an active liver disease.
  • i.You are HIV positive.
  • j.You have a history of cancer with in the past 5 years (except for skin cancer that has been successfully treated).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration Study
EUCTR2004-003807-19-ESMerck & Co Inc.600
Active, not recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaMedDRA version: 7.0Level: LLTClassification code 10027762
EUCTR2004-003807-19-ATMerck, Sharp & Dohme600
Active, not recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaMedDRA version: 7.0Level: LLTClassification code 10027762
EUCTR2004-003807-19-HUMerck & Co., Inc.600
Completed
Not Applicable
The study for beneficial efficacy and safety of ezetimibe in patients with hyper LDL-cholesterolemia associated with diabetes mellitus (DM) including glucose intolerance and non-alcoholic fatty liver disease (NAFLD)non-alcoholic fatty liver disease, diabetes mellitus, hyper LDL-cholesterolemia
JPRN-UMIN000004462Geriatric Medicine, Osaka University Graduate School of Medicine20
Not yet recruiting
Phase 2
Exploratory survey of the safety and efficacy of endoscopic radiofrequency ablation for malignant biliary strictureMalignant biliary stricture
JPRN-UMIN000031601Graduate School of Medicine, Chiba University10